
    
      This is an open-label, non-comparative phase II clinical trial. Approximately thirty-three
      patients will be enrolled in order to obtain twenty-nine evaluable subjects who received two
      cycles of study treatment in Simon's 2-stage optimal design.

      Duration of subject involvement: Study treatment should be administered up to disease
      progression, intolerable toxicity, or consent withdrawal.

      Recruitment period: 10 months
    
  